Babar Ghias serves as the Chief Financial Officer at BioCryst Pharmaceuticals Inc., a biopharmaceutical company focused on developing innovative treatments for rare diseases. Appointed to the role in June 2023, Ghias brings over two decades of experience in finance leadership within the biotechnology and pharmaceutical sectors. His strategic oversight includes managing the company's financial operations, capital allocation, investor relations, and treasury functions, playing a pivotal role in supporting BioCryst's commercial growth and pipeline advancement, particularly for its lead product, ORLADEYO (berotralstat). Prior to joining BioCryst, Ghias was CFO at Turning Point Therapeutics from 2020 to 2022, where he led financial strategy during the company's rapid expansion and its subsequent $4.1 billion acquisition by Bristol Myers Squibb. He previously held the position of Senior Vice President of Finance and Treasurer at Puma Biotechnology, overseeing global financial planning, SEC reporting, and a $200 million equity financing. Earlier in his career, Ghias spent a decade at Deloitte in various audit and advisory roles, gaining deep expertise in biotech financials, and held finance positions at Orexigen Therapeutics. Ghias holds a Bachelor of Science in Accounting from California State University, Fullerton, and is a Certified Public Accountant (CPA). His achievements include successfully navigating multiple financings, mergers, and operational turnarounds, earning recognition for driving sustainable growth in high-stakes biotech environments. At BioCryst, he continues to fortify the company's financial foundation amid expanding global operations and R&D investments.